Dr. Morris on the Efficacy of 177Lu-PSMA-617 Plus Best SOC in mCRPC

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

Michael J. Morris, MD, medical oncologist, section head, Prostate Cancer, GU Oncology, Memorial Sloan Kettering Cancer Center, discusses the efficacy of Lutetium 177 (177Lu) PSMA-617 (177Lu-PSMA-617) as a treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

The phase 3 VISION trial (NCT03511664), which examined the addition of 177Lu-PSMA-617 to best standard-of-care therapy in patients with mCRPC, showed that the agent is safe and can prolong survival in a paradigm where few other therapeutic options are available, according to Morris. Additionally, quality-of-life data will soon read out and complement data already reported on other clinical end points of the study, Morris adds.

In addition to overall survival and radiographic progression-free survival, another important end point was time to first symptomatic skeletal event (SSE). The risk of SSEs was reduced by 50%. In the past, findings like this have been known to serve as the basis for the approval of other therapeutics in prostate cancer, Morris notes. Moreover, the prostate-specific antigen decline rate and the overall response rate were higher in the 177Lu-PSMA-617 arm vs the control arm. Collectively, data from the trial suggest that 177Lu-PSMA-617 plus standard-of-care therapy is superior to standard-of-care therapy alone for this patient population, Morris concludes.